Other languages Bolt Biotherapeutics, Inc.

Equities

BOLT

US0977021049

Market Closed - Nasdaq Other stock markets 01:30:00 29/06/2024 am IST			5-day change	1st Jan Change
0.75 ^USD	+0.32%		+0.01%	-33.04%

20/05	Bolt Biotherapeutics, Inc. Announces Management Changes	CI
20/05	Bolt Biotherapeutics, Inc. Announces Chief Executive Officer Changes	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Bolt Biotherapeutics, Inc. Announces Management Changes	20/05
Bolt Biotherapeutics, Inc. Announces Chief Executive Officer Changes	20/05
Top Midday Decliners	15/05
Bolt Biotherapeutics Stops Development of Trastuzumab Imbotolimod, Cuts Workforce by 50%	15/05
Top Premarket Decliners	15/05
Investors Await Key Inflation Data for April as US Futures Remain Flat in Wednesday's Premarket	15/05
Bolt Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	15/05
Bolt Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	22/03
Bolt Biotherapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	22/03
Bolt Biotherapeutics Enrolls First Patient in Phase 2 Clinical Study Evaluating Bdc-1001 in Patients with Her2-Positive Breast Cancer Previously Treated with Enhertu	05/12
Bolt Biotherapeutics Insider Sold Shares Worth $128,993, According to a Recent SEC Filing	01/12
Bolt Biotherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	10/11
Bolt Biotherapeutics, Inc. Presents Updated Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at ESMO 2023 Congress	23/23/23
Bolt Biotherapeutics Begins Dosing in Advanced Cancers Phase 1/2 Study of BDC-3042	17/23/17
Sector Update: Health Care Stocks Rising in Late Afternoon Trading	29/23/29
Sector Update: Health Care Stocks Higher in Afternoon Trading	28/23/28
Bolt Biotherapeutics Says US FDA Granted Orphan Drug Designation for BDC-1001 for Gastric Cancer	28/23/28
Bolt Biotherapeutics Says Candidate Cancer Treatment Secures Patent	12/23/12
Bolt Biotherapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	08/23/08
Bolt Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	12/23/12

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Bolt Biotherapeutics, Inc.

Equities

BOLT

US0977021049

Other languages

Filters